Tumor-Educated Platelets Facilitate Thrombus Formation Through Migration.

cancer-associated thrombosis cell migration hypercoagulable state plasma tumor-educated platelets

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 19 01 2022
accepted: 28 01 2022
entrez: 14 3 2022
pubmed: 15 3 2022
medline: 15 3 2022
Statut: epublish

Résumé

Platelets are small anucleate cells that circulate in the blood and form thrombi. Tumor-educated platelets are the platelets derived from cancer patients. Although many have reported that tumor-educated platelets are associated with cancer-associated thrombosis, their function in this process is poorly understood. Here we first collect the clinical data from 100 different cancer patients, showing that cancer patients are in a hypercoagulable state. Our experiment shows that tumor-educated platelets from melanoma-burdened mouse models can migrate faster and longer, forming more clots (thrombus). However, the plasma from tumor mice can inhibit platelet migration. The RNA sequence profile of tumor-educated platelets shows that many genes associated with cell migration and cell skeleton expressed significantly higher. Our research offers a new insight into the tumor-educated platelets to better understand the thrombus formation.

Identifiants

pubmed: 35280750
doi: 10.3389/fonc.2022.857865
pmc: PMC8907878
doi:

Types de publication

Journal Article

Langues

eng

Pagination

857865

Informations de copyright

Copyright © 2022 Liu, Wang, Liao, Song and Yao.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Rev Immunol. 2019 Dec;19(12):747-760
pubmed: 31409920
Blood. 2015 Oct 15;126(16):1877-84
pubmed: 26330242
Blood. 2013 Sep 12;122(11):1873-80
pubmed: 23798713
Thromb Haemost. 2008 Mar;99(3):466-72
pubmed: 18327393
Blood. 2019 May 30;133(22):2359-2364
pubmed: 30833413
Cell. 2017 Nov 30;171(6):1368-1382.e23
pubmed: 29195076
Blood. 2009 Jan 29;113(5):1112-21
pubmed: 18802008
Bio Protoc. 2018 Sep 20;8(18):e3018
pubmed: 34395806
Blood. 2012 Apr 12;119(15):3394-402
pubmed: 22337717
Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16900-5
pubmed: 17075060
Transfus Apher Sci. 2015 Feb;52(1):12-8
pubmed: 25599988
J Hematol Oncol. 2019 Mar 7;12(1):26
pubmed: 30845955
Genome Biol. 2014;15(12):550
pubmed: 25516281
Blood. 2021 Jun 10;137(23):3192-3200
pubmed: 33940593
Transfusion. 2012 May;52 Suppl 1:9S-19S
pubmed: 22578375
Thromb Res. 2020 Feb;186:80-85
pubmed: 31918352
Nat Rev Immunol. 2011 Apr;11(4):264-74
pubmed: 21436837
Cancer Cell. 2015 Nov 9;28(5):666-676
pubmed: 26525104
Cancers (Basel). 2018 Oct 11;10(10):
pubmed: 30314362
J Exp Med. 2003 Jan 6;197(1):41-9
pubmed: 12515812
Cancer Cell. 2018 Jun 11;33(6):965-983
pubmed: 29657130
Front Behav Neurosci. 2020 Jul 14;14:115
pubmed: 32760256
Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2341-9
pubmed: 21071698

Auteurs

Zheming Liu (Z)

Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.

Jing Wang (J)

Reproductive Medicine Centre, Zhongshan Hospital, Fudan University, Shanghai, China.

Fuben Liao (F)

Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.

Qibin Song (Q)

Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.

Yi Yao (Y)

Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.

Classifications MeSH